Moderna, Merck mRNA cancer vaccine prevents melanoma from returning

Prevents melanoma from returning, according to the two companies who'd very much like you to buy it. Peer review comes later.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…

Read it at The Hill ↗

← Front page